Atossa Therapeutics, Inc. (ATOS) Stock Forecast
ATOS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $19.00 average of analyst targets
- Upside to target
- +552.9% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.86
- 52-week range
- $1.75 – $15.15
ATOS analyst ratings
2 analystsNumber of analysts at each rating.
ATOS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ATOS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.78 | −$0.78 | −$0.78 | −$1.05 | +25.7% | 1 |
| Current fiscal year (2026) | −$3.56 | −$3.56 | −$3.56 | −$4.04 | +11.9% | 1 |
| Next fiscal year (2027) | −$3.30 | −$3.30 | −$3.30 | −$3.56 | +7.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ATOS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
ATOS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ATOS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.10 | −$1.10 | −$1.10 | −$1.10 | −$0.78 | −29.1% | 1 up · 0 down |
| Current fiscal year (2026) | −$4.40 | −$4.40 | −$4.40 | −$4.40 | −$3.56 | −19.1% | 1 up · 0 down |
| Next fiscal year (2027) | −$4.38 | −$4.38 | −$4.38 | −$4.38 | −$3.30 | −24.7% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ATOS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ATOS beat in 8 of 12.
What analysts expect from ATOS
2 analysts cover Atossa Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $19.00, 552.9% above the latest close of $2.91. Analysts expect earnings of −$3.56 per share for 2026, +11.9% from a year earlier. For 2027 the average estimate is −$3.30 per share. Atossa Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: ATOS income statement, ATOS key metrics, ATOS chart. See the ATOS stock overview for the latest quote and news.
ATOS forecast FAQ
What is Atossa Therapeutics's price target?
The average analyst price target for Atossa Therapeutics is $19.00, 552.9% above the latest close of $2.91.
Is Atossa Therapeutics a buy, hold or sell?
Of 2 analysts covering Atossa Therapeutics, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Atossa Therapeutics's EPS forecast?
Analysts forecast −$3.56 per share for 2026 (range −$3.56 to −$3.56); for 2027 the estimate is −$3.30.
When does Atossa Therapeutics report earnings?
Atossa Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.86.
Does Atossa Therapeutics usually beat earnings estimates?
Atossa Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.